TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Frequently asked questions
What sector does TetraLogic Pharmaceuticals Corp (TLOG) operate in?
TetraLogic Pharmaceuticals Corp belongs to the Healthcare sector and operates in the Biotechnology industry.
What is TetraLogic Pharmaceuticals Corp (TLOG) current stock price?
As of the latest data, TetraLogic Pharmaceuticals Corp stock price is $0.00, with a previous close of $0.00.
What is TetraLogic Pharmaceuticals Corp (TLOG) current market capitalization?
TetraLogic Pharmaceuticals Corp market cap is approximately 2.45 thousand.
What is TetraLogic Pharmaceuticals Corp (TLOG) Earnings Per Share (EPS)?
The trailing EPS is -$0.01.
Does TetraLogic Pharmaceuticals Corp (TLOG) pay dividends?
No. TetraLogic Pharmaceuticals Corp does not pay a dividend.
What is TetraLogic Pharmaceuticals Corp (TLOG) beta (volatility) score?
TetraLogic Pharmaceuticals Corp has a beta of -73.602, indicating lower volatility than the overall market.
